These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 27213960)
1. Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Seywright A; Torrance HJ; Wylie FM; McKeown DA; Lowe DJ; Stevenson R Clin Toxicol (Phila); 2016 Sep; 54(8):632-7. PubMed ID: 27213960 [TBL] [Abstract][Full Text] [Related]
2. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study. Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903 [TBL] [Abstract][Full Text] [Related]
3. Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project. Bäckberg M; Tworek L; Beck O; Helander A J Med Toxicol; 2017 Mar; 13(1):52-60. PubMed ID: 27638057 [TBL] [Abstract][Full Text] [Related]
5. Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples. Franz F; Angerer V; Moosmann B; Auwärter V Drug Test Anal; 2017 May; 9(5):744-753. PubMed ID: 27504870 [TBL] [Abstract][Full Text] [Related]
6. Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist. Meyyappan C; Ford L; Vale A Clin Toxicol (Phila); 2017 Feb; 55(2):151-152. PubMed ID: 27635694 [No Abstract] [Full Text] [Related]
7. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Hermanns-Clausen M; Müller D; Kithinji J; Angerer V; Franz F; Eyer F; Neurath H; Liebetrau G; Auwärter V Clin Toxicol (Phila); 2018 Jun; 56(6):404-411. PubMed ID: 29072524 [TBL] [Abstract][Full Text] [Related]
8. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Abouchedid R; Hudson S; Thurtle N; Yamamoto T; Ho JH; Bailey G; Wood M; Sadones N; Stove CP; Dines A; Archer JRH; Wood DM; Dargan PI Clin Toxicol (Phila); 2017 Jun; 55(5):338-345. PubMed ID: 28421836 [TBL] [Abstract][Full Text] [Related]
9. Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. Gaunitz F; Lehmann S; Thomas A; Thevis M; Rothschild MA; Mercer-Chalmers-Bender K Int J Legal Med; 2018 Nov; 132(6):1645-1657. PubMed ID: 30219927 [TBL] [Abstract][Full Text] [Related]
10. MDMB-CHMICA: Availability, Patterns of Use, and Toxicity Associated With This Novel Psychoactive Substance. Haden M; Archer JR; Dargan PI; Wood DM Subst Use Misuse; 2017 Jan; 52(2):223-232. PubMed ID: 27759479 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples. Hess C; Murach J; Krueger L; Scharrenbroch L; Unger M; Madea B; Sydow K Drug Test Anal; 2017 May; 9(5):721-733. PubMed ID: 27400642 [TBL] [Abstract][Full Text] [Related]
12. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA. Adamowicz P; Gieroń J Clin Toxicol (Phila); 2016 Sep; 54(8):650-4. PubMed ID: 27227269 [TBL] [Abstract][Full Text] [Related]
13. Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA. Westin AA; Frost J; Brede WR; Gundersen PO; Einvik S; Aarset H; Slørdal L J Anal Toxicol; 2016; 40(1):86-7. PubMed ID: 26353925 [No Abstract] [Full Text] [Related]
14. Chemical profiling of the synthetic cannabinoid MDMB-CHMICA: Identification, assessment, and stability study of synthesis-related impurities in seized and synthesized samples. Münster-Müller S; Hansen S; Opatz T; Zimmermann R; Pütz M Drug Test Anal; 2019 Aug; 11(8):1192-1206. PubMed ID: 31124282 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats. Krotulski AJ; Garibay N; Walther D; Walton SE; Mohr ALA; Logan BK; Baumann MH Neuropharmacology; 2021 Nov; 199():108800. PubMed ID: 34547333 [TBL] [Abstract][Full Text] [Related]
16. In vitro Phase I metabolism of indazole carboxamide synthetic cannabinoid MDMB-CHMINACA via human liver microsome incubation and high-resolution mass spectrometry. Presley BC; Logan BK; Jansen-Varnum SA Drug Test Anal; 2019 Aug; 11(8):1264-1276. PubMed ID: 31108568 [TBL] [Abstract][Full Text] [Related]
17. A Novel Impurity-Profiling Workflow with the Combination of Flash-Chromatography, UHPLC-MS, and Multivariate Data Analysis for Highly Pure Drugs: A Study on the Synthetic Cannabinoid MDMB-CHMICA. Münster-Müller S; Zimmermann R; Pütz M Anal Chem; 2018 Sep; 90(17):10559-10567. PubMed ID: 30079731 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Synthetic Cannabinoid Metabolites in Human Blood in the Absence of Parent Compounds: A Stability Assessment. Krotulski AJ; Bishop-Freeman SC; Mohr ALA; Logan BK J Anal Toxicol; 2021 Feb; 45(1):60-68. PubMed ID: 32435808 [TBL] [Abstract][Full Text] [Related]
19. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents? Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429 [TBL] [Abstract][Full Text] [Related]
20. The impact of the Psychoactive Substances Act 2016 on the online availability of MDMB-CHMICA. Haden M; Wood DM; Dargan PI QJM; 2017 Oct; 110(10):619-622. PubMed ID: 28339898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]